Skip to Content

Elekta AB ADR EKTAY Stock Quote

| Rating as of


Morningstar‘s Stock Analysis EKTAY

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics EKTAY

Company Profile EKTAY

Business Description

Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company's installed base of more than 5,000 linear accelerators, GammaKnife and Unity platforms, and software is used in more than 6,000 hospitals globally. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and Asia-Pacific contributing the remainder.

Kungstensgatan 18, Box 7593
Stockholm, SE-103 93, Sweden
T +46 858725400
Industry Medical Instruments & Supplies
Most Recent Earnings Oct 31, 2022
Fiscal Year End Apr 30, 2023
Employees 4,664